ClinicalTrials.gg
RecruitingNCT04837547PEACHUpdated Nov 4, 2026

PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy

A Phase 1 interventional study of Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT) in Neuroblastoma and Diffuse Intrinsic Pontine Glioma, sponsored by University of Florida. Recruiting at 3 sites in United States. Open to participants aged 1 Year to 30 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by University of Florida · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 2 months later.
Updated Nov 4, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
1 Year to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 469 studies in Neuroblastoma with a site in United States — 54 open to participants now, 103 under way, 4 of them phase 3. Neuroblastoma · United States.

Planned enrollment
229th of 379
24 · median 31
Started
2021
with 11 others
Phase 1
176 of 469
15 open now
Primary completion
2027-09
later than 55 of 100 live
Registered
421st of 469
by date

Among the 469 studies in Neuroblastoma with a site in United States, this one is the 229th largest by planned enrollment of the 379 interventional ones that give a count, is one of 12 that started in 2021, is one of 176 in phase 1, reaches primary completion later than 55 of the 100 other live ones, and was the 421st registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

54 of the 469 studies in Neuroblastoma with a site in United States are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.

This study: 1 Year to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 469 studies in Neuroblastoma with a site in United States, or all of them as a file.
02

Study summary

A Phase I open-label, multicenter study, to evaluate the safety, feasibility, and maximum tolerated dose (MTD) of treating children with newly diagnosed DIPG or recurrent neuroblastoma with molecular targeted therapy in combination with adoptive cell therapy (Total tumor mRNA-pulsed autologous Dendritic Cells (DCs) (TTRNA-DCs), Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT) and Autologous G-CSF mobilized Hematopoietic Stem Cells (HSCs)).

03

Conditions studied

  • Neuroblastoma
  • Diffuse Intrinsic Pontine Glioma
04

Who can participate

Ages eligible
1 Year to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have proven pediatric cancer with confirmation at diagnosis or at the time of recurrence/progression and clinical determination of disease for which there is no known effective curative therapy or disease that is to established proven therapies fitting into one of the following categories:
  • Disease Status:

High Risk Neuroblastoma-

  1. Patients that have relapsed following standard of care therapy or having progressed during standard of care therapy and non-responsive/progressive to accepted curative chemotherapy.
  2. Neuroblastoma must be age >12 months at enrollment

Diffuse Intrinsic Pontine (or other brain stem) Glioma

  1. Newly-diagnosed patients willing to undergo
  2. Must be within 2 months of diagnosis and prior to starting radiation
  3. DIPG must be ≥ 3 years of age at enrollment

    • All subjects must be age ≤ 30 years at enrollment
    • Patient and/or parents/guardian willing to consent to biopsy for obtaining tumor material for confirmatory diagnosis and/or tumor RNA extraction and amplification.
    • Subjects must have as defined Per section 8 at the time of biopsy and tumor or bone marrow must be accessible for biopsy. Tumor or bone marrow samples submitted for analysis must contain >20% viable tumor tissue to qualify. Note: Subjects with NB who are expected to have no evidence of disease after surgical removal of their tumor are still eligible for this trial if their disease would normally require chemotherapy treatment after surgery despite NED status.
    • Current disease state must be one for which there is currently no known effective therapy
    • Specimens will be obtained only in a non-significant risk manner and not solely for the purpose of testing.
    • Lansky or Score must be ≥ 60
    • Bone Marrow:

      1. (Absolute neutrophil count) ≥ 1000/µl (unsupported- >24 hrs off G-CSF and 7 days off neulasta)
      2. ≥ 100,000/µl (can be transfused)
      3. > 8 g/dL (can be transfused)
    • Renal: Serum creatinine ≤ upper limit of institutional normal.
    • Adequate liver function must be demonstrated, defined as:

      1. Total ≤ 1.5 x (ULN) for age AND
      2. (SGPT) ≤ 3 times upper limit of normal (ULN) for age
      3. AST (SGOT) ≤ 3 times upper limit of normal (ULN) for age.
    • Subjects with CNS disease currently taking must have been on a stable dose of steroids for at least one week prior to their biopsy and must not have progressive hydrocephalus at enrollment.
    • A negative serum pregnancy test is required for female participants of (≥13 years of age or after onset of menses)
    • Both male and female post-pubertal study subjects need to agree to use one of the more effective methods during treatment and for six months after treatment is stopped. These methods include total abstinence (no sex), oral contraceptives ("the pill"), an intrauterine device (IUD), levonorgestrel implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be used, contraceptive foam with a condom is recommended.
    • : All subjects and/or legal guardians must sign informed written consent. Assent, when appropriate, will be obtained according to institutional guidelines
    • Post-Biopsy: Patients with post-biopsy neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration.

Exclusion criteria

Exclusion Criteria:

  • Absence of tumor on specimen or a diagnosis other than NBL or glioma on biopsy
  • Known or disease or infection.
  • Subjects with significant renal, cardiac, pulmonary, hepatic or other organ dysfunction.
  • Prior allergic reaction to GM-CSF or Td.
  • Subjects who have received any cytotoxic chemotherapy within the last 7 days prior to biopsy or focal radiotherapy in the case of patients with diffuse intrinsic pontine (or other brain stem) gliomas
  • Subjects with NBL who have received any radiotherapy to the primary sample site within the last 14 days (radiation may be included in treatment decision after biopsy).
  • Subjects receiving any drug concurrently.
  • Subjects with uncontrolled serious infections or a life-threatening illness (unrelated to tumor)
  • Subjects with any other medical condition, including malabsorption syndromes, mental illness or substance abuse, deemed by the Investigator to be likely to interfere with the interpretation of the results or which would interfere with a subject's ability to sign or the legal guardian's ability to sign the , and subject's ability to cooperate and participate in the study
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Arm 1: Subjects with Diffuse Intrinsic Pontine Glioma (DIPG).

    This Phase I study is will utilize a standard 3+3 dose escalation design to establish the MTD and will evaluate the following three pre-specified dose levels of xALT: Dose Level 1: 3 x10\^7 cells/kg Dose Level +1: 3 x10\^8 cells/kg Dose Level -1: 3 x10\^6 cells/kg The dose escalation scheme will be evaluated for Arm 1 and Arm 2 separately. For each Study Arm, a minimum of 4 DLT evaluable subjects and a maximum of 12 DLT evaluable subjects will be enrolled (a total of 8 to 24 DLT evaluable subjects).

    Biological: Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)

  • Experimental
    Arm 2: Relapsed/Refractory Neuroblastoma (NB)

    This Phase I study is will utilize a standard 3+3 dose escalation design to establish the MTD and will evaluate the following three pre-specified dose levels of xALT: Dose Level 1: 3 x10\^7 cells/kg Dose Level +1: 3 x10\^8 cells/kg Dose Level -1: 3 x10\^6 cells/kg The dose escalation scheme will be evaluated for Arm 1 and Arm 2 separately. For each Study Arm, a minimum of 4 DLT evaluable subjects and a maximum of 12 DLT evaluable subjects will be enrolled (a total of 8 to 24 DLT evaluable subjects).

    Biological: Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose Limiting Toxicities as a Measure of Safety and Tolerability

    To evaluate the dose-limiting toxicities (DLTs) and to establish the maximum tolerated dose (MTD) of treating children with molecular targeted therapy in combination with adoptive cellular therapy

    Time frame: 2 years

Secondary outcomes

  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability

    To evaluate the overall safety profile of study treatment

    Time frame: 2 years plus 30 days

  2. Number of Participants that are able to have vaccine produced and delivered

    To evaluable the feasibility of producing and administering the protocol directed therapy

    Time frame: 2 years

  3. Number of participants with progression free survival (PFS) during study

    To determine the activity of treatments chosen based on Progression free survival (PFS)

    Time frame: 7 years

  4. Number of participants with overall survival (OS) during study

    To determine the activity of treatments chosen based on Overall Survival (OS)

    Time frame: 7 years

  5. Determine the Overall Response Rate (ORR) of Participants using INSS Response Evaluation Criteria for NB and RANO criteria for DIPG

    To determine the activity of treatments chosen based on Overall Response Rate (ORR)

    Time frame: 2 years

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Sep 2027, 72 months after the start.

Of 73 non-industry phase 1 interventional studies under Neuroblastoma, half reached primary completion within 89 months of starting (the median), counting those still running; a quarter within 65 and three quarters within 117. This study's planned 72 months is below that.

Counting every sponsor, half of 86 studies reached it within 83 months; a quarter within 60 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2021
First posted
Apr 8, 2021
StartActual
Sep 20, 2021
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2032
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Nov 4, 2026
Sites
3 sites changed recruiting status (2 now recruiting, 1 now active, not recruiting)
Show 3 sites
  • University of Florida · Gainesville, United Statesno status→Recruiting
  • Levine Children's Hospital · Charlotte, United Statesno status→Active, not recruiting
  • Penn State Milton S. Hershey Medical Center and Children's Hospital · Hershey, United Statesno status→Recruiting
Nov 4, 2026
Contact
Study contact now listed: added B•••@pennstatehealth.psu.edu · •••0003. See the current contact
Nov 4, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • University of Florida · Gainesville, United StatesContact added m•••@neurosurgery.ufl.edu · •••9050Contact added (no phone or email listed)
  • Penn State Milton S. Hershey Medical Center and Children's Hospital · Hershey, United StatesContact added E•••@pennstatehealth.psu.eduContact added (no phone or email listed)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Active, not recruiting→Recruiting
    3 sites changed recruiting status (2 now recruiting, 1 now active, not recruiting)
    Show 3 sites
    • University of Florida · Gainesville, United Statesno status→Recruiting
    • Levine Children's Hospital · Charlotte, United Statesno status→Active, not recruiting
    • Penn State Milton S. Hershey Medical Center and Children's Hospital · Hershey, United Statesno status→Recruiting
    Contact Study contact now listed: added B•••@pennstatehealth.psu.edu · •••0003. See the current contact
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • University of Florida · Gainesville, United StatesContact added m•••@neurosurgery.ufl.edu · •••9050Contact added (no phone or email listed)
    • Penn State Milton S. Hershey Medical Center and Children's Hospital · Hershey, United StatesContact added E•••@pennstatehealth.psu.eduContact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04837547
Collaborators
Beat Childhood Cancer Research Consortium
Responsible party
Sponsor
First posted
Apr 8, 2021
Start date
Sep 20, 2021
Primary completion
Sep 2027 (estimated)
Completion
Sep 2032 (estimated)
Last update
Nov 4, 2026

Study contacts

BCC Enroll
Contact
BCCEnroll@pennstatehealth.psu.edu
717-531-0003
Giselle Sholler, MD
study chair · Beat Childhood Cancer at Penn State University
Duane Mitchell, M.D., Ph.D.
study chair · University of Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Total Tumor mRNA-pulsed Tumor-specific Ex vivo-expanded Autologous Lymphocyte Transfer Cells

Start the discussion